about
The role of the GP in follow-up cancer care: a systematic literature review.Using routine inpatient data to identify patients at risk of hospital readmission.Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkersA new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugSurvival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients.Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.The effects of tai chi in centrally obese adults with depression symptoms.Resveratrol--pills to replace a healthy diet?Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease.Therapeutic drug monitoring of antimicrobials.Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical methodTherapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.Prevalence of medication discrepancies in patients with cirrhosis: a pilot study.Can paracetamol (acetaminophen) be administered to patients with liver impairment?Achieving the World Health Organization's vision for clinical pharmacologyStatins and clinical outcomes in heart failure.Diagnostic errors in older patients: a systematic review of incidence and potential causes in seven prevalent diseasesThe challenge of costly drugs.Statins and congestive heart failure.Acidosis in the hospital setting: is metformin a common precipitant?Role of statins in diabetes complications.Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis.Assessment of nonischemic myocardial fibrosis.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.Minimizing inappropriate medications in older populations: a 10-step conceptual framework.Target concentration intervention in oncology: where are we at?Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review.BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin.Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches.Clinical consequences of a miscalibrated digoxin immunoassay.Ezetimibe: Use, costs, and adverse events in Australia.Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.The Impact of Model-Misspecification on Model Based Personalised Dosing.Medicines optimisation in older people: Taking age and sex into account.Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia.Reducing inappropriate polypharmacy: the process of deprescribing.
P50
Q30241957-58487076-6369-4D3B-AFC5-4A5EC50B34E1Q33463892-304AB6D6-5E2D-4FD5-A38E-E91BAC833774Q33701694-8DC89794-E11A-4C75-9CAC-127EF0298E9BQ34065271-370C3C4D-B44D-4CC6-A5B9-B9A9C712CC0EQ34467975-8562C865-D616-4FDD-BF3D-BB511DD29A4EQ34831840-E38AB83B-8A85-458A-A069-C149EE1BDA36Q35061229-D8911688-76F4-4615-B19D-756C1F2780EAQ35120581-2B381124-FB50-4E37-B0A0-1741DC48E797Q35332315-12608EED-F7FF-4675-8F58-D88A06792629Q35640430-408D380C-3495-4561-9396-9FD0E3E08FC0Q35718063-C095DF9D-704D-4B69-B9D8-1446A2CEFE8AQ36111191-26F3A87F-8D10-4C10-9D6A-1F5818411BAEQ36130230-0BA71665-23F6-4581-8F8A-AFB9FA17C2A7Q36802077-8E926727-82CB-40A5-9020-FD20A648B12BQ36802085-22295735-624A-4784-99DC-A8A049088159Q36864678-2E2E6070-A677-4E53-A348-AD2EC6251E88Q36940073-A7D44144-7F55-43E4-AEFB-B9E8D8A0875DQ37033787-A5029C77-708D-4634-8C26-DA0E7957C2E4Q37244729-E94744DE-73F4-494D-B3D9-F44FEC92EC31Q37424243-F0D7181F-D9C2-4F47-BD06-E8CC7A82D056Q37581658-A4D3DBC4-E80B-4672-ADD4-D4C37B44B3F7Q37767169-10F56CF0-3A49-4544-AE02-B20BF087F1CAQ37771633-84A04277-63E3-45A5-8E36-86DFADD9B6A4Q37837059-130E5DDA-9992-4D21-9AFB-FDF8D8A15B65Q37990090-221746E4-8313-4271-BF1E-0B39DDA68467Q38010071-8F7795BD-006E-4850-8FC4-EE733598780AQ38037349-2ED66CBF-F42D-43C6-A526-2CF49B41DC05Q38123193-445DB420-79F3-4D01-99E4-508920C37324Q38173297-4F7BC92D-9104-4C0D-9143-5120228700E3Q38235088-315DAEB3-F4C4-4167-8DC3-BE611385CE85Q38404338-E4F8A24C-1FA6-4252-BACF-D3B71E5ED6A1Q38507706-56A23F58-BB63-4DF4-84A5-07C0096857F3Q38563371-A845BB88-5626-43CB-B589-1BA0C83C0345Q38587724-B04823F2-1348-4C33-9477-C0E5A9D5658CQ38736405-D4E71571-FD69-48EF-881C-E12424098E90Q38852665-331F1A23-4DE1-4C45-A04F-A82FA81CE37CQ38922975-69C9957C-EA47-4BB7-9F4B-BF6D9A08455DQ38931118-08CB8E01-DACE-4F6D-9ED3-CFCC05B4AA44Q38987559-1AF8D423-05AD-4B63-820E-1EAAB684D37DQ39026437-2944D85F-EF7F-4085-934E-4FEAA6D760BB
P50
description
Australian researcher
@en
rexercor australian
@lfn
wetenschapper
@nl
name
Jennifer Martin
@ast
Jennifer Martin
@en
Jennifer Martin
@es
Jennifer Martin
@nl
Jennifer Martin
@sl
type
label
Jennifer Martin
@ast
Jennifer Martin
@en
Jennifer Martin
@es
Jennifer Martin
@nl
Jennifer Martin
@sl
prefLabel
Jennifer Martin
@ast
Jennifer Martin
@en
Jennifer Martin
@es
Jennifer Martin
@nl
Jennifer Martin
@sl
P106
P1153
35582674200
P21
P214
806144647698695429023
P31
P496
0000-0002-8614-0199
P734
P735
P7859
viaf-806144647698695429023